Make a power point presentation of 25 slides on hypertensive disorders in pregnancy mainly pre eclampsia definition etiopathology in detail prevention prediction of pre eclampsia investigations and it's management from standard textbooks
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Running Command
Writing File
Running Command
Running Command
Your presentation is ready:
Hypertensive Disorders Pregnancy PE
Presentation · PPTX
Here is exactly what was built into the 25 slides:
| # | Slide Title |
|---|---|
| 1 | Title slide — Hypertensive Disorders in Pregnancy |
| 2 | Overview / Topics Covered |
| 3 | Classification (Gestational HTN, PE, Eclampsia, Chronic HTN, Superimposed PE) |
| 4 | Definition of Pre-eclampsia — ACOG diagnostic criteria |
| 5 | Pre-eclampsia WITH Severe Features |
| 6 | Epidemiology & Risk Factors |
| 7 | Etiopathogenesis — Two-Stage Model (Overview) |
| 8 | Stage 1: Abnormal Trophoblast Invasion & Spiral Artery Remodeling |
| 9 | Stage 2: Angiogenic Imbalance — sFlt-1, PlGF, sEng, VEGF |
| 10 | Genetic, Immunological & Maternal Factors |
| 11 | Pathophysiology — Multi-Organ Effects (Kidney, Liver, CNS, Haematologic, etc.) |
| 12 | Prediction — 1st Trimester FMF Screening (MAP + UtA-PI + PAPP-A + PlGF) |
| 13 | Prediction — 2nd Trimester sFlt-1/PlGF Ratio & Doppler |
| 14 | Prevention — Low-Dose Aspirin (ASPRE Trial, USPSTF Grade B) |
| 15 | Prevention — Calcium, Antioxidants, LMWH |
| 16 | Investigations — Labs, Biomarkers, Imaging, Fetal Assessment |
| 17 | Management Philosophy — 3 Tenets |
| 18 | Timing of Delivery by Gestational Age |
| 19 | Antihypertensive Therapy — Labetalol, Hydralazine, Nifedipine |
| 20 | Magnesium Sulfate — Seizure Prophylaxis & Toxicity Monitoring |
| 21 | HELLP Syndrome — Criteria, Classification, Management |
| 22 | Eclampsia — Step-by-step management protocol |
| 23 | Postpartum Care & Long-Term Cardiovascular Risk |
| 24 | Fetal & Perinatal Considerations (FGR, Dopplers, Steroids) |
| 25 | Key Takeaways |
Sources used: Creasy & Resnik's Maternal-Fetal Medicine (9th Ed.), ACOG guidelines, ASPRE Trial (Rolnik 2017), Magpie Trial, USPSTF Grade B recommendation, WHO guidelines.
This is a shared conversation. Sign in to Orris to start your own chat.